[ad_1]
What you need to know every morning.
The National Institute of Pulmonology in Koranyi is also participating in the clinical trial of the nationally developed drug favipiravir, the institution’s acting director general told MTI on Saturday.
The study looks at how effective the drug is in people with coronavirus infections, how safe it can be given, and at what stage of infection.
Gábor Takács, the chief pharmacist of the Korányi department, called favipiravir the last promising option in the treatment of coronavirus. He said the drug is not completely unknown, Japan and China have already used it in other indications to treat the flu. However, recent data suggests that it is also effective in treating coronavirus.
According to Takács, a clinical trial lasts for months, is carried out according to a serious methodology and in the end a biostatistical evaluation is carried out. Because the study was recently launched, it will take several more months to determine if favipiravir is truly an effective drug for coronavirus infection. (MTI)
[ad_2]
